Immunoglobulins for clinical use undergo rigorous testing to ensure their safety and efficacy. The testing process includes screening for infectious agents like viruses and bacteria to prevent disease transmission. Additionally, immunoglobulins are tested for their purity, concentration, and antibody activity to ensure they are effective in conferring immunity. Safety tests also include checking for the presence of harmful substances like endotoxins. Furthermore, clinical trials are conducted to assess the efficacy and safety of immunoglobulins in treating specific conditions. Regulatory bodies, such as the FDA and EMA, set stringent standards that these products must meet before they are approved for clinical use.

Yes, passive immunity can sometimes lead to adverse reactions in recipients, though this is relatively rare. Adverse reactions are typically associated with immunoglobulin infusions, such as those used in Intravenous Immunoglobulin (IVIG) therapy. Potential reactions include allergic responses, especially in individuals with IgA deficiency who might react to IgA present in the IVIG preparation. Other possible reactions include flu-like symptoms, headache, fever, nausea, and in rare cases, more severe reactions like anaphylaxis. These reactions are generally manageable and the benefits of IVIG therapy in providing immediate immunity often outweigh the risks, especially in immunocompromised patients.

Ethical considerations in the sourcing and administration of immunoglobulins include donor consent and safety, fair access to treatment, and the responsible use of resources. Donors must provide informed consent, understanding the use of their blood or plasma for immunoglobulin production. Their health and well-being are also paramount, with regular health checks and ethical treatment being crucial. In terms of administration, it's important to ensure equitable access to immunoglobulin therapies, particularly for patients in low-income countries or marginalized communities. Additionally, ethical use of these resources involves balancing the demand for immunoglobulins with the availability and the need to use them in medically justified situations.

Passive immunity is considered temporary because the externally acquired antibodies are gradually broken down and not replenished by the recipient's immune system. Unlike active immunity, where memory cells are created, passive immunity does not involve a lasting immune memory. The duration of passive immunity depends on the half-life of the antibodies, which is typically around 21 to 28 days for IgG. Therefore, passive immunity usually lasts for a few weeks to a few months. Over time, as these antibodies diminish, the protection they offer also decreases, leaving the individual reliant on their own immune response or further passive immunisation for continued protection.

Passive immunity differs from active immunity primarily in its source and duration. In passive immunity, antibodies are acquired from an external source, such as breast milk or immunoglobulin infusions, and do not involve the recipient's immune system's active response to pathogens. This form of immunity offers immediate protection but is temporary, typically lasting only a few weeks to months. In contrast, active immunity involves the production of antibodies by the immune system in response to exposure to an antigen, either through infection or vaccination. Active immunity is generally long-lasting, often providing lifelong protection, due to the formation of memory cells that remember the specific pathogen.